Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Wants A Breakthrough Therapy, Even Without All The Standards

Executive Summary

A few requests have gone to FDA for candidates to be named breakthrough therapies and gain access to shorter development programs, but the agency has not established all the program requirements yet.

You may also be interested in...



US FDA's Biologics Center Director Expects It Soon Will See 'Growth Spurt'

With cell and gene therapies becoming more popular, CBER Director Marks says in an interview with the Pink Sheet that more staff may be needed soon.

Breakthrough Designation Can Be 'Lever' For Manufacturing Evolution, FDA Says

CDER Director Woodcock notes breakthrough program often pushes sponsors to modernize production processes.

Primer On FDA’s "Breakthrough Therapy" Program

A look at the genesis of the US expedited regulatory pathway for drugs and biologics, its benefits, and how the program is working today.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054838

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel